8,331 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by Diversify Advisory Services LLC

Diversify Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 8,331 shares of the biopharmaceutical company’s stock, valued at approximately $344,000.

Other large investors have also recently added to or reduced their stakes in the company. Rise Advisors LLC bought a new position in Halozyme Therapeutics during the first quarter worth $25,000. Principal Securities Inc. acquired a new stake in Halozyme Therapeutics in the fourth quarter worth $34,000. First Horizon Advisors Inc. increased its position in Halozyme Therapeutics by 24.5% in the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 293 shares during the period. Parkside Financial Bank & Trust acquired a new stake in Halozyme Therapeutics in the fourth quarter worth $64,000. Finally, Headlands Technologies LLC increased its position in Halozyme Therapeutics by 1,068.2% in the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 1,613 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Trading Down 0.9 %

Shares of NASDAQ HALO opened at $51.56 on Friday. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $53.22. The firm has a market capitalization of $6.56 billion, a PE ratio of 21.31, a PEG ratio of 0.52 and a beta of 1.27. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The business has a 50-day moving average price of $46.61 and a two-hundred day moving average price of $40.89.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.07. The business had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. As a group, analysts predict that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HALO. Benchmark increased their target price on Halozyme Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. Piper Sandler lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $48.00 to $51.00 in a research report on Friday, June 7th. JMP Securities dropped their target price on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. Finally, HC Wainwright reissued a “buy” rating and set a $65.00 price target on shares of Halozyme Therapeutics in a report on Monday, June 24th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.25.

View Our Latest Stock Report on Halozyme Therapeutics

Insider Activity at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the transaction, the chief financial officer now directly owns 15,480 shares of the company’s stock, valued at approximately $803,876.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 40,000 shares of company stock valued at $1,858,100. Corporate insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.